Abstract
The promise of pharmacogenomics lies in the potential to establish a personalized drug therapy with the intent of maximizing effectiveness and minimizing risk, through development of pharmacogenomics biomarkers. However, currently, most pharmacogenomic measurements are not considered valid biomarkers with clear clinical significance, thus this field is in early developmental stages. Recently, the development of comprehensive, high-throughput technologies such as gene expression microarrays has provided powerful new tools for these stages. This technological transformation is, at the same time, generating an increasing demand for statistical analysis of large and complex multivariate datasets from high-throughput assays. This article provides a review of the key features to be observed in statistical analyses of large amounts of data from pharmacogenomic biomarker studies with high-throughput assays. The problem of false positive can be very serious in such studies. The evaluation of stability and reproducibility of the results of statistical analysis are claimed to reduce chance that false positive findings are subject to further investigation in subsequent studies.
Keywords: Pharmacogenomics, biomarkers, high-throughput technology, statistical analysis, false positives
Current Drug Safety
Title: Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies
Volume: 1 Issue: 2
Author(s): Shigeyuki Matsui
Affiliation:
Keywords: Pharmacogenomics, biomarkers, high-throughput technology, statistical analysis, false positives
Abstract: The promise of pharmacogenomics lies in the potential to establish a personalized drug therapy with the intent of maximizing effectiveness and minimizing risk, through development of pharmacogenomics biomarkers. However, currently, most pharmacogenomic measurements are not considered valid biomarkers with clear clinical significance, thus this field is in early developmental stages. Recently, the development of comprehensive, high-throughput technologies such as gene expression microarrays has provided powerful new tools for these stages. This technological transformation is, at the same time, generating an increasing demand for statistical analysis of large and complex multivariate datasets from high-throughput assays. This article provides a review of the key features to be observed in statistical analyses of large amounts of data from pharmacogenomic biomarker studies with high-throughput assays. The problem of false positive can be very serious in such studies. The evaluation of stability and reproducibility of the results of statistical analysis are claimed to reduce chance that false positive findings are subject to further investigation in subsequent studies.
Export Options
About this article
Cite this article as:
Matsui Shigeyuki, Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies, Current Drug Safety 2006; 1 (2) . https://dx.doi.org/10.2174/157488606776930517
DOI https://dx.doi.org/10.2174/157488606776930517 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets Natural Products and their Analogues as Efficient Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry Phosphorothioate-Stimulated Uptake of siRNA by Mammalian Cells: A Novel Route for Delivery
Current Topics in Medicinal Chemistry Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma
Current Cancer Therapy Reviews The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Mucoadhesive Polymers for Delivery of Drugs to the Oral Cavity
Recent Patents on Drug Delivery & Formulation Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Imiquimod
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Current Cancer Therapy Reviews Clinical Proteomics in Cancer Research
Current Proteomics